Pulmonology · page 3

Astegolimab cut COPD exacerbations by 15% regardless of eosinophil count

A pooled analysis of ALIENTO and ARNASA in 2,682 patients found an anti-ST2 antibody reduced moderate and severe exacerbations by 15% on a fortnightly schedule, and severe exacerbations by 32% — in a population enrolled irrespective of blood eosinophils. Dupilumab separately cut emergency visits by 38% in the eosinophilic phenotype.